EGFR with TKI-sensitive mutations in exon 19 is highly expressed and frequently detected in Chinese patients with lung squamous carcinoma

Figures & data

Table 1 Clinicopathological features of patients with lung squamous cell carcinoma

Variables (n)	Number of patients (%)
Median age (min–max)	64 (41–81)
Cigarette smoking
Smoker	45 (50.5)
Nonsmoker	35 (39.3)
No data available	9 (10.1)
TNM stage
I	4 (4.4)
II	37 (41.5)
III	22 (24.7)
IV	26 (29.2)
Total	89

Abbreviation: TNM, tumor node metastasis.

Figure 1 DGGE gel images of mutation analysis of EGFR exon 19.

Notes: (A) Result of DGGE system verification. M: EGFR exon 19 mutation detection marker. 1: No template; 2–4: specimen 203 that harbored deletion 1 mutation (positive sample [PS]); 5–7: specimen 231, no mutation in exon 19 (negative sample [NS]); 8: specimen 203 that harbored deletion 1 mutation (positive sample [PS]); 9: specimen 231, no mutation in exon 19 (negative sample [NS]); 10: no template; 11: negative control (using wild type exon 19 fragment cloned in plasmid as PCR template); 12: positive control of Del-1 (using exon 19 harboring Del-1 mutation cloned in plasmid as PCR template). (B) Detection of EGFR exon 19 mutation in squamous cell carcinoma specimens by DGGE. M: marker; 1: 203; 2: 23; 3: 89; 4: 177; 5: 25; 6: 244; 7: 38; 8: 71; 9: 5; 10: 202; 11: 468; 12: 10; 13: 466; 14: 476; 15: 473; 16: 481; 17: 482; 18: 483. a: deletion 1; b: wild type; c: deletion 2; d: M2; e: M4; f: M5; g: M1; h: M2; i: M3; j: M6.
Abbreviations: DGGE, denature gel gradient electrophoresis; PCR, polymerase chain reaction.

Table 2 EGFR exon 19 mutation profile of SCC patients

Mutation type	Nomenclature	Nucleotide changes	Amino acid changes	Number of patients (%)	References
Deletion	Del-1	c.2240-2254_del	Leu747-Thr751_del	50 (64.9)	^Citation24 COSP4242*
	Del-2	c.2237-2251_del	Glu746-Thr751_del	18 (23.3)	^Citation18
Point mutation	M1	c.2225T.C,	val742Ala,	1 (1)	This study
		c.2230A.G,	Ile744Val,
		2237A.G,	Glu746Gly
		2238A.G*	Glu746Gly*
	M2	c.2274A.G*	Glu758Glu*	4 (4.4)	This study
	M3	c.2210A.G,*	Lys737Arg,	1 (1)	This study
		c.2274A.G	Glu758Glu
	M4	c.2212G.T*	Val737Phe,*	1 (1)
		c.2225T.C,	val742Ala,		This study
		c.2230A.G,	Ile744Val,
		c.2237A.G,	Glu746Gly,
		c.2238A.G	Glu746Gly*
		c.2274A.G	Glu758Glu
	M5	c.2238A.G,*	Glu746Gly,*	1 (1)	This study
		c.2246A.T*	Glu749Val,
		c.2274A.G	Glu758Glu
	M6	c.2234A.C,	Lys747Thr,	1 (1)	SCV000062071.2*
		c.2280C.T	Leu760leu

Note:

* Accession number of catalogue of somatic mutations in cancer (COSMIC) (http://cancer.sanger.ac.uk/cosmic).

Abbreviation: SCC, squamous cell carcinoma.

Table 3 Distribution of eight kinds of mutation in different SCC stages

SCC stage	Number of patients	Del-1	Del-2	M1	M2	M3	M4	M5	M6
I	4	2	0	0	1	0	0	0	0
II	37	18	9	1	1	1	1	0	1
III	22	15	1	0	2	0	0	1	0
IV	26	15	8	0	0	0	0	0	0
Total	89	50	18	1	4	1	1	1	1

Abbreviation: SCC, squamous cell carcinoma.

Table 4 Comparison of EGFR exon 19 mutational profile between smoking and nonsmoking patients

Smoke history in years	Number of patients	Number of patients without mutation	Del-1	Del-2	M1	M2	M3	M4	M5	M6
<25	7	0	6 (85.7%)	1 (14.2%)	0	0	0	0	0	0
~30	19	0	9 (47.3%)	7 (36.8%)	0	1 (5.2%)	1 (5.2%)	0	0	1 (5.2%)
~40	11	3 (27.2%)	4 (36.3%)	1 (9%)	0	2 (18.1%)	0	0	1 (9%)	0
>50	8	1 (12.5%)	6 (75%)	0	0	1 (12.5%)	0	0	0	0
Nonsmoker	35	8 (22.8%)	19 (54.2%)	6 (17.1%)	1 (2.8%)	0	0	1 (2.8%)	0	0
No data available	9	0	6 (66.6%)	3 (33.3%)	0	0	0	0	0	0

Figure 2 Comparison of the proportion of mutated EGFR between different SCC stage patients.

Note: **P<0.01.
Abbreviation: SCC, squamous cell carcinoma.

ShahiRBDe BrakeleerSDe GreveJGeersCIn’t VeldPTeugelsEDetection of EGFR–TK domain-activating mutations in NSCLC with generic PCR-based methodsAppl Immunohistochem Mol Morphol201523316317125751592

 PubMedGoogle Scholar

MuXLLiLYZhangXTGefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in Chinese patients with non-small cell lung cancerClin Cancer Res200511124289429415958609

 PubMed Web of Science ®Google Scholar